# US 2025/0082768 A1 · Conjugating reagents and conjugates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082768 A1
- Document ID: US20250082768A1
- Status: Published application
- Kind: A1
- Application number: 18/291,380
- Filed: 2022-07-26
- Published: 2025-03-13
- Earliest claimed: 2021-07-26
- Assignees: Cambridge Enterprise Limited
- Applicants: Cambridge Enterprise Limited
- Inventors: David Robert Spring; Stephen James Walsh; Friederike Marie Dannheim
- Web page: https://patentgrep.com/patent/US20250082768A1

## CPC

- A61K 47/6867: {the tumour determinant being from a cell of a blood cancer}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/32: against translation products of oncogenes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to antibody conjugates, and methods of manufacturing the same. In particular, the present invention relates to a conjugate comprising an antibody, a linker and at least one active agent, wherein: the linker connects the at least one active agent(s) to the antibody; ii) the linker is attached to the antibody through 5 to 8 independent covalent bonds; and iii) each covalent bond between the linker and the antibody is formed from the reaction between a sulfur atom on the antibody and a functional group on the linker.

## Claims

### Claim 1

A conjugate comprising an antibody, a linker and at least one active agent, wherein:
i) the linker connects the at least one active agent(s) to the antibody;
ii) the linker is attached to the antibody through 5 to 8 independent covalent bonds; and
iii) each covalent bond between the linker and the antibody is formed from the reaction between a sulfur atom on the antibody and a functional group on the linker.

### Claim 2 (depends on 1)

The conjugate according to claim 1, wherein linker is attached to the antibody through 6 to 8 independent covalent bonds such that the linker re-bridges between two and four reduced interchain disulfide bonds in the antibody.

### Claim 3 (depends on 1, 2)

The conjugate according to claim 1 or claim 2, wherein linker is attached to the antibody through 8 independent covalent bonds such that the linker re-bridges four reduced interchain disulfide bonds in the antibody.

### Claim 4 (depends on 1, 2, 3)

The conjugate according to any one of claims 1 to 3, wherein the conjugate comprises between one and four re-bridging moieties of Formula (III), shown below:
wherein:
ZA is a functional linking group;
Pep indicates the position where the moiety is attached to the antibody, either directly or indirectly; and
indicates the position where the moiety is attached to linker.

### Claim 5 (depends on 4)

The conjugate according to claim 4, wherein the conjugate comprises between three and four re-bridging moieties of Formula (III).

### Claim 6 (depends on 4, 5)

The conjugate according to claim 4 or 5, wherein the re-bridging moieties of Formula (III) are independently selected from the one of the following groups:
wherein:
one or two of A1, A2 and A3 are N and the other one or two of A1, A2 and A3 are CH, or all three of A1, A2 and A3 are N or CH;
a and b are integers selected from 0 or 1;
X is selected from N, NRN, O and S, wherein RN is H or C1-2alkyl;
R1 and R2 are independently selected from C1-C6 alkylene and C1-C6 alkylene containing O in the backbone;
R3 is selected from hydrogen or a C1-C4 alkyl;
Y1 and Y2 are independently absent or selected from O, NR4, C(═O), C(═O)NR4 or NR5C(═O);
p and q are independently integers selected from 0 or 1;
Q is CR6, N or aryl;
R4, R5 and R6 are independently selected from hydrogen and C1-C4alkyl;
Pep indicates the position where the moiety is linked to the antibody, either directly or indirectly; and
indicates the position where the moiety is attached to linker.

### Claim 7 (depends on 4, 5, 6)

The conjugate according to any one of claims 4 to 6, wherein the re-bridging moieties each have the general Formula (IIIa), shown below:
wherein each of A1, A2, A3, X, Pep and
are as defined in claim 6.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The conjugate according to any one of claims 1 to 7, wherein the conjugate is of Formula (IIIA), shown below:
wherein:
Z1 is a re-bridging moiety of Formula (III) as defined in claim 6 or claim 7 above that is attached to an antibody at the positions shown in Formula (III);
each Q1 is independently a bond or a group of Formula IVa:
wherein:
Q1A is absent or selected from a C(═O), OC(═O), NR7C(═O), C(═NR8) and C(═S);
Q1B is selected from O, N, S and CR9CR10;
R7, R8, R9 and R10 are independently selected from hydrogen and C1-C4alkyl;
R20 and R21 are independently selected from a bond, a C1-C10 alkylene and a C1-C10 alkylene containing O in the backbone; and
v is an integer selected from 0, 1 or 2;
each Q2 is independently selected from N and CR11, wherein R11 is selected from hydrogen and C1-C4alkyl;
each Q3 is independently a group of Formula IVb:
wherein:
Q3A is selected from NR12, O and S;
Q3B and Q3C are independently selected from a bond, O and NR13;
R12 and R13 are independently selected from hydrogen and C1-C4alkyl;
R22 and R23 are independently selected from a bond, a C1-C10alkylene and a C1-C10alkylene containing O in the backbone;
Q3D is absent or selected from C(═O), OC(═O), NR12C(═O) and C(═O)NR12;
W1 is a group of Formula IVc or Formula IVe:
wherein:
W1A is selected from N and CR14, wherein R14 is a selected from hydrogen and C1-C4alkyl;
LW is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing amino, O or N in the backbone;
Ring A is a 6-membered aryl, a 6-membered heteroaryl, a 6-membered heterocyclyl or a 6-membered cycloalkyl, wherein X, is selected from CH or N;
W1B is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR15C(═O)—, —C(═O)NR15—, —NR15C(═O)NR16—, —C(═NR15)— and —C(═S)—;
R15 and R16 are independently selected from hydrogen and C1-C4alkyl;
R23 and R24 are independently selected from a bond, C1-C12alkylene and C1-C12alkylene containing O in the backbone;
m is an integer selected from 1 or 2;
W1C is selected from Formula WQ1 or Formula WC2:
wherein:
WQ1 is a group of Formula WC3:
wherein:
QW1 is absent or selected from a C1-C12alkylene and a C1-C12alkylene containing O or N in the backbone; and
QW2 is selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —NHC(═O)—, and —C(═O)NH—;
y is an integer selected from 0 or 1;
XW1 is selected from O or NH;
XW2 is selected from hydrogen, C1-C4alkyl, ORx1 and NRx1Rx2, wherein Rx1 and Rx2 are independently selected from hydrogen and C1-C4alkyl;
indicates the position where XW1 is attached to a group of formula WQ2;
indicates the position where WQ1 is attached to a group of formula R24
WQ2 is a group of Formula WC4:
wherein:
QW1A is absent or selected from a C1-C12alkylene and a C1-C12alkylene containing O or N in the backbone; and
QW2A is selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —NHC(═O)—, and —C(═O)NH—; LQ1 is a linker comprising one or more groups selected from a C1-C20alkylene, an alkylenediamine moiety, a (poly)ethylene glycol moiety, an amino acid residue and combinations thereof;
XW3 is selected from O or NH:
indicates the position where XW4 is attached to another group of formula WQ2 via the QW2A substituent group, or
indicates the position where XW4 is attached to one of the following groups: a hydrogen or —C(═O)RX3, wherein Rx3 is selected from hydrogen and C1-C4alkyl;
indicates the position where QW2A is attached to the group of formula WQ1 via the XW1 group;
XW4 is selected from O or NH;
LQ1 is a linker comprising one or more groups selected from a C1-C20alkylene, an alkylenediamine moiety, a (poly)ethylene glycol moiety, an amino acid residue and combinations thereof
t is an integer selected from 1 to 8;
FG′ is a functional linking moiety;
L1 is a linker; and
D is an active agent;
W2 is a group of Formula IVd:
wherein:
W2A is selected from N and CR17;
W2B is a group selected from N, CR18, —C(═O)N— and —C(═O)CR18—;
W2C is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR17C(═O)—, —C(═O)NR17—, —NR17C(═O)NR18—, —C(═NR17)— and —C(═S)—;
L2W is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing amino, O or N in the backbone;
R17 and R18 are independently selected from hydrogen and C1-C4alkyl;
R25 and R26 are independently selected from a bond, C1-C6alkylene and C1-C6alkylene containing O in the backbone; and
FG′, L1 and D are as defined above;
r is an integer selected from 0 to 12;
s is an integer selected from 0 to 6; and
wherein r and s are selected such that the total number of active agents per conjugate is between 1 and 12.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The conjugate according to any one of claims 1 to 8, wherein the conjugate is of Formula (IIIA), shown below:
wherein:
Z1 is a re-bridging moiety of Formula (III) as defined in claim 6 or claim 7 above that is attached to a antibody at the positions shown in Formula (III);
each Q1 is independently a bond or a group of Formula IVa:
wherein:
Q1A is absent or selected from a C(═O), OC(═O), NR7C(═O), C(═NR8) and C(═S);
Q1B is selected from O, N, S and CR9CR10;
R7, R8, R9 and R10 are independently selected from hydrogen and C1-C4alkyl;
R20 and R21 are independently selected from a bond, a C1-C8 alkylene and a C1-C8alkylene containing O in the backbone; and
v is an integer selected from 0, 1 or 2;
each Q2 is independently selected from N and CR11, wherein R11 is selected from hydrogen and C1-C4alkyl;
each Q3 is independently a group of Formula IVb:
wherein:
Q3A is selected from NR12, O and S;
Q3B and Q3C are independently selected from a bond, O and NR13;
R12 and R13 are independently selected from hydrogen and C1-C4alkyl;
R22 and R23 are independently selected from a bond, a C1-C8alkylene and a C1-C8alkylene containing O in the backbone;
Q3D is absent or selected from C(═O), OC(═O), NR12C(═O) and C(═O)NR12,
W1 is a group of Formula IVc1 or Formula IVe1:
wherein:
W1A is selected from N and CR14, wherein R14 is a selected from hydrogen and C1-C4alkyl;
LW is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing O or N in the backbone:
Ring A is a 6-membered aryl, a 6-membered heteroaryl, a 6-membered heterocyclyl or a 6-membered cycloalkyl, wherein X, is selected from CH or N;
W1B is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR15C(═O)—, —C(═O)NR15—, —NR15C(═O)NR16—, —C(═NR15)— and —C(═S)—;
R15 and R16 are independently selected from hydrogen and C1-C4alkyl;
R23 and R24 are independently selected from a bond, a C1-C8alkylene and a C1-C6alkylene containing O in the backbone;
m is an integer selected from 1 or 2; and
FG′ is a functional linking moiety;
L1 is a linker; and
D is an active agent;
W2 is a group of Formula IVd:
wherein:
W2A is selected from N and CR17;
W2B is a group selected from N, CR18, —C(═O)N— and —C(═O)CR18—;
WC2 is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR17C(═O)—, —C(═O)NR17—, —NR17C(═O)NR18—, —C(═NR17)— and —C(═S)—;
L2W is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing O or N in the backbone;
R17 and R18 are independently selected from hydrogen and C1-C4alkyl;
R25 and R26 are independently selected from a bond, a C1-C8alkylene and a C1-C8alkylene containing O in the backbone; and
FG′, L1 and D are as defined above;
r is an integer selected from 0 to 12;
s is an integer selected from 0 to 6; and
wherein r and s are selected such that the total number of active agents per conjugate is between 1 and 12.

### Claim 10 (depends on 6, 8, 9)

The conjugate according to claim 8 or claim 9, wherein Z1 is a re-bridging moiety of Formula (IIIa), shown below:
wherein each of A1, A2, A3, X, Pep and
are as defined in claim 6.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The conjugate according to any one of claims 1 to 10, wherein the antibody is a monoclonal antibody.

### Claim 12 (depends on 4, 5, 6, 7, 8, 9, 10, 11)

The conjugate according to any one of claims 4 to 11, wherein at least two of the re-bridging moieties are separated by between 10 and 60 atoms.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The conjugate according to any one of claims 1 to 12, wherein the conjugate is selected from one of the following conjugates:
wherein:
II indicates the position where the antibody is attached; and
the antibody is trastuzumab or brentuximab, suitably trastuzumab.

### Claim 14

A conjugating reagent of Formula (II), shown below:
(D-L1-FG′)n-L-(Z)8 (Formula II)
wherein:
FG′ is a functional linking moiety;
n is an integer selected from 0 to 20;
L and L′ are independently linkers;
Z is a functional group capable of reaction with a sulfur atom from a cysteine of an antibody; and
D is an active agent;
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

### Claim 15 (depends on 14)

A conjugating reagent according to claim 14, wherein the conjugating reagent is of Formula (IIa), shown below:
(D-L1-FG′)n-L-(Z2)4 (Formula IIa)
wherein:
Z2 is a re-bridging linking group comprising two functional groups capable of reaction with a sulfur atom from a cysteine moiety of an antibody; and
L, L′, FG′ and n are as defined in claim 14.

### Claim 16 (depends on 6, 14, 15)

A conjugating reagent according to claim 14 or claim 15, wherein the conjugating reagent is selected from one of the following groups:
wherein:
A1, A2, A3, X, R1, R2, R3, Y1, Y2, Q, p and 1 are each as defined in claim 6;
Ts is a tosylate;
FG′, L, L1, n and D are as defined in claim 14.

### Claim 17 (depends on 8, 9, 14, 15, 16)

A conjugating reagent according to any one of claims 14 to 16, wherein the conjugating reagent is of Formula (IIc), shown below:
wherein:
Z2 is a re-bridging linking group comprising two functional groups capable of reaction with a sulfur atom from a cysteine of an antibody;
Q1, Q2, Q3, W1, W2′, r and s are as defined in claim 8 or claim 9.

### Claim 18 (depends on 17)

A conjugating reagent according to claim 17, wherein Z2 is a group of Formula III, shown below:
wherein:
two of A1, A2 and A3 are N and the other of A1, A2 and A3 is CH;
X is selected from NRN, O and S, wherein RN is H or C1-2 alkyl; and
denotes the point of attachment to Q1.

### Claim 19 (depends on 14, 15, 16, 17, 18)

A conjugating reagent according to any one of claims 14 to 18, wherein the conjugating reagent is selected from:

### Claim 20

A compound of Formula (I), shown below:
(FG)n-L-(Z)8 (Formula I)
wherein:
FG is a functional group capable reacting with another moiety to form a functional linking moiety;
n is an integer selected from 0 to 20;
L is a linker; and
Z is a functional group capable of reaction with a sulfur atom from a cysteine moiety of an antibody;
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

### Claim 21 (depends on 20)

A compound according to claim 20, wherein the compound is of Formula (Ia), shown below:
(FG)n-L-(Z2)4 (Formula Ia)
wherein:
Z2 is a re-bridging linking group comprising two functional groups capable of reaction with a sulfur atom from a cysteine or lysine moiety of an antibody;
L, FG and n are as defined in claim 20 above.

### Claim 22 (depends on 6, 20, 21)

A compound according to any one of claims 20 to 21, wherein the compound is selected from one of the following groups:
wherein:
A1, A2, A3, X, R1, R2, R3, Y1, Y2, Q, p and 1 are each as defined in claim 6;
Ts is a tosylate;
L and FG are as each defined in claim 20 above.

### Claim 23 (depends on 6, 8, 9, 18, 20, 21, 22)

A compound according to any one of claims 20 to 22, wherein the compound is of Formula (Ic), shown below:
wherein:
Z2 is as defined in claim 18 or 21 or Z2 is a group of Formula (III) as defined in claim 6;
Q1, Q2, Q3, r and s are as defined in claim 8 or claim 9;
W1 is a group of Formula IVc2, Formula IVe2 or Formula IVc:
wherein:
W1A is selected from N and CR14, wherein R14 is a selected from hydrogen and C1-C4alkyl;
LW is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing amino, O or N in the backbone;
Ring A is a 6-membered aryl, a 6-membered heteroaryl, a 6-membered heterocyclyl or a 6-membered cycloalkyl, wherein X1 is selected from CH or N;
W1B is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR15C(═O)—, —C(═O)NR15—, —NR15C(═O)NR16—, —C(═NR15)— and —C(═S)—;
R15 and R16 are independently selected from hydrogen and C1-C4alkyl;
R23 and R24 are independently selected from a bond, a C1-C8alkylene and a C1-C8alkylene containing O in the backbone;
m is an integer selected from 1 or 2;
W1C is a group of Formula WC2:
wherein:
WQ1 is a group of Formula WC3:
wherein:
QW1 is absent or selected from a C1-C12alkylene and a C1-C12alkylene containing O or N in the backbone; and
QW2 is selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —NHC(═O)—, and —C(═O)NH—;
y is an integer selected from 0 or 1;
XW1 is selected from O or NH;
XW2 is selected from hydrogen, C1-C4alkyl, ORX1 and
NRx1Rx2, wherein Rx1 and Rx2 are independently selected from hydrogen and C1-C4alkyl;
indicates the position where XW1 is attached to a group of formula WQ2;
indicates the position where WQ1 is attached to a group of formula R24
WQ2 is a group of Formula WC4B:
wherein:
QW1A is absent or selected from C1-C12alkylene and C1-C12alkylene containing O or N in the backbone; and
QW2A is selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —NHC(═O)—, and —C(═O)NH—;
XW3 is selected from O or NH;
indicates the position where XW4 is attached to another group of formula WQ2 via the QW2A substituent group, or
indicates the position where XW4 is attached to one of the following groups hydrogen or —C(═O)RX3, wherein Rx3 is selected from hydrogen and C1-C4alkyl;
indicates the position where QW2A is attached to the group of formula W1 via the XW1 group;
XW4 is selected from 0 or NH:
LQ1 is a linker comprising one or more groups selected from a C1-C20alkylene, an alkylenediamine moiety, a (poly)ethylene glycol moiety, an amino acid residue and combinations thereof;
t is an integer selected from 1 to 8;
FG is as defined in claim 20;
W2′ is a group of Formula IVd:
wherein:
W2A is selected from N and CR17, wherein R17 is a selected from hydrogen and C1-C4alkyl;
W2B is a group selected from N, CR18, —C(═O)N— and —C(═O)CR18—;
W2C is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR17C(═O)—, —C(═O)NR17—, —NR17C(═O)NR18—, —C(═NR17)— and —C(═S)—;
L2W is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing amino, O or N in the backbone;
R17 and R18 are independently selected from hydrogen and C1-C4alkyl;
R25, R26 and R27 are independently selected from a bond, C1-C8alkylene and C1-C8alkylene containing O in the backbone; and
FG is as in claim 20.

### Claim 24 (depends on 8, 9, 18, 20, 21, 22, 23)

A compound according to any one of claims 20 to 23, wherein the compound is of Formula (Ic), shown below:
wherein:
Z2 is as defined in claim 18 or 21;
Q1, Q2, Q3, r and s are as defined in claim 8 or claim 9;
W1′ is a group of Formula IVc2:
wherein:
W1A is selected from N and CR14, wherein R14 is a selected from hydrogen and C1-C4alkyl;
LW is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing O or N in the backbone;
W1B is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR15C(═O)—, —C(═O)NR15—, —NR15C(═O)NR16—, —C(═NR15)— and —C(═S)—;
R15 and R16 are independently selected from hydrogen and C1-C4alkyl;
R23 and R24 are independently selected from a bond, C1-C8alkylene and C1-C6alkylene containing O in the backbone;
m is an integer selected from 1 or 2; and
FG is as defined in claim 20;
W2′ is a group of Formula IVd:
wherein:
W2A is selected from N and CR17, wherein R17 is a selected from hydrogen and C1-C4alkyl;
W2B is a group selected from N, CR13, —C(═O)N— and —C(═O)CR18—;
W2C is a group selected from —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —NR17C(═O)—, —C(═O)NR17—, —NR17C(═O)NR18—, —C(═NR17)— and —C(═S)—;
L2W is absent or selected from a C1-C6alkylene and a C1-C6alkylene containing O or N in the backbone;
R17 and R13 are independently selected from hydrogen and C1-C4alkyl;
R25, R26 and R27 are independently selected from a bond, C1-C8alkylene and C1-C8alkylene containing O in the backbone; and
FG is as in claim 20.

### Claim 25 (depends on 23, 24)

A compound according to claim 23 or 24, wherein Z2 is a group of Formula III, shown below:
wherein:
two of A1, A2 and A3 are N and the other of A1, A2 and A3 is CH;
X is selected from N, NRN, O and S, wherein RN is H or C1-2alkyl; and
denotes the point of attachment to Q1.

### Claim 26 (depends on 20, 21, 22, 23, 24, 25)

A compound according to any one of claims 20 to 25, wherein FG is selected from an alkene, an alkyne, an azide, a hydroxyl, an amine, a carboxylic acid, an aldehyde, an acyl halide, a tetrazine, an alkoxyamine (e.g. hydroxylamine), a hydrazine, an electron-rich dienophile (e.g. a 1,3-nitrone alkene) and an electron-poor diene (e.g. tetrazine), nitrone, an isocyanate and an isothiocyanate.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25, 26)

A compound according to any one of claims 20 to 26, wherein FG is selected from an alkyne or an azide.

### Claim 28 (depends on 20, 21, 22, 23, 24, 25, 26, 27)

A compound according to any one of claims 20 to 27, wherein the compound is selected from:

### Claim 29 (depends on 20, 21, 22, 23, 24, 25, 26, 27)

A compound according to any one of claims 20 to 27, wherein the compound is selected from:

### Claim 30 (depends on 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19)

A conjugate according to any one of claims 8 to 13, or a conjugating reagent according to any one of claims 15 to 19, wherein FG′ is selected from
—NH(═O)C— and —C(═O)NH—.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A conjugate according to any one of claims 1 to 13, or a conjugating reagent according to any one of claims 14 to 19, wherein the active agent is a cytotoxin, optionally selected from the group comprising auristatins, maytansinoids, tubulysins, calicheamicins, duocarmycins, pyrrolobenzodiazepines, camptothecin analogues and doxorubicin.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A conjugate according to any one of claims 1 to 13, or a conjugating reagent according to any one of claims 14 to 19, wherein the conjugate comprises between 1 and 8 active agents.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 13, 14, 15, 20, 21, 22)

A conjugate according to any one of claims 1 to 7, or a conjugating reagent according to any one of claims 13 to 15, or a compound according to any one of claims 20 to 22, wherein the linker (L) comprises one or more groups selected from an alkylenediamine moiety, a polyethylene glycol moiety and an amino acid residue.

### Claim 34 (depends on 14, 20)

A conjugating reagent according to claim 14, or a compound according to claim 20, wherein Z is a Michael Acceptor.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising, a conjugate according to any one of claims 1 to 13, and a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 30, 31, 32, 33)

A conjugate according to claims 1 to 13 and 30 to 33, for use in the treatment of a proliferative disease.
